Co-Diagnostics, Inc. Reports Continued Sales Momentum for Q3 2019
Revenue includes sales of infectious disease, mosquito abatement products and AgBio primer design services
Management Discussion
“The Company’s joint venture in
“Co-Diagnostics has recently participated in numerous mosquito abatement conferences including events in
“The Company is also strongly encouraged by the progress of its AgBio sector, particularly in conjunction with its previously announced agreements with LGC, Biosearch Technologies (“LGC”), a global leader in the design, development, and manufacture of sophisticated, custom oligonucleotide-based tools and associated reagents for applied markets. LGC is owned by funds affiliated with
“Company representatives presented research findings on rare allele detection for liquid biopsy announced in Q3 at the 4th Advances in Circulating Tumor Cells (ACTC) conference, held
About
Forward-Looking Statements:
This press release contains forward-looking statements. Forward-looking statements can be identified by words such as "believes," "expects," "estimates," "intends," "may," "plans," "will" and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Forward-looking statements in this release include statements regarding the (i) use of funding proceeds, (ii) expansion of product distribution, (iii) acceleration of initiatives in liquid biopsy and SNP detection, (iv) use of the Company’s liquid biopsy tests by laboratories, (v) capital resources and runway needed to advance the Company’s products and markets, (vi) increased sales in the near-term, (vii) flexibility in managing the Company’s balance sheet, (viii) anticipation of business expansion, and (ix) benefits in research and worldwide accessibility of the CoPrimer technology and its cost-saving and scientific advantages. Forward-looking statements are subject to inherent uncertainties, risks and changes in circumstances. Actual results may differ materially from those contemplated or anticipated by such forward-looking statements. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191113005161/en/
Source:
Andrew Benson
Head of Investor Relations
+1 801-438-1036
investors@codiagnostics.com